KDM1A and medulloblastoma: Based on the very recent observations that (1) several mutations occur in histone demethylation pathways in medulloblastomas, (2) aberrant H3K4 methylation is associated with dismal prognosis in a subset of medulloblastoma patients and (3) KDM1A is a promising H3K4 modifying epigenetic target in several cancers, including other embryonal tumors, which controls broad expression programs during cellular development and malignant progression, we hypothesized that KDM1A might also be an important functional player in medulloblastoma.